SIGA Technologies, Inc. reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, with total revenues of $94.6 million, down from $138.7 million in 2024. This decrease was primarily driven by a reduction in product sales, which fell to $88.0 million from $133.3 million the previous year. The company attributed this decline to lower sales of its lead product, TPOXX®, particularly in international markets, where revenues dropped to $5.8 million from $23.0 million. Despite the revenue drop, SIGA maintained a net income of $23.3 million, although this was a decrease from $59.2 million in 2024.
In terms of operational changes, SIGA has made strategic adjustments to its procurement contracts, particularly with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The 19C BARDA Contract, which includes the delivery of TPOXX® to the Strategic National Stockpile, has been modified to redefine the quantity of IV TPOXX® courses. As of December 31, 2025, the contract contemplates up to approximately $630 million in payments, with $545.2 million related to exercised options. The company has also been focusing on expanding its product offerings, including a potential supplemental New Drug Application for a smallpox post-exposure prophylaxis indication, targeting submission within the next twelve months.
SIGA's operational metrics indicate a shift in focus, with the company reporting a headcount of 49 full-time employees as of February 2026, a slight increase from previous years. The company continues to rely on third-party manufacturers for the production of TPOXX®, which has been a critical aspect of its supply chain strategy. The company has also been working on transitioning the manufacturing of IV TPOXX® to a new third-party site, following the notification from its current manufacturer about the closure of its production line.
Looking ahead, SIGA faces several challenges, including the need to secure new contracts with the U.S. Government to maintain its revenue stream. The company has expressed concerns about the potential impact of macroeconomic volatility, including changes in tariffs and trade policies, on its operating results. Additionally, SIGA is navigating the complexities of international sales and regulatory approvals, particularly in light of recent clinical trial results for TPOXX® in treating mpox, which may affect its market position. The company remains optimistic about its future, particularly regarding the anticipated outcomes of ongoing regulatory assessments and the potential for new product indications.
About SIGA TECHNOLOGIES INC
SIGA Technologies is a pharmaceutical company specializing in antiviral drugs, notably TPOXX (tecovirimat), for smallpox and other orthopoxvirus infections. It supplies government and international markets, focusing on biodefense and pandemic preparedness. The company relies on third-party manufacturers, holds extensive patents, and navigates complex regulatory environments globally to develop and commercialize its antiviral therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.